{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:20:31Z","timestamp":1780320031984,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jval.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:43:34Z","timestamp":1728492214000},"page":"108-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes"],"prefix":"10.1016","volume":"28","author":[{"given":"Erica G.","family":"Horodniceanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswi","family":"Datla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena N.","family":"Murugappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Kanapuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Amiri-Kordestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Larkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kluetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2024.09.009_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.jval.2024.09.009_bib3","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jval.2024.09.009_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jval.2024.09.009_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib10","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in Phase I clinical trials","volume":"113","author":"Veitch","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jval.2024.09.009_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jval.2024.09.009_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jnci\/djy181","article-title":"Blinding and patient-reported outcome completion rates in US Food and Drug Administration cancer trial submissions, 2007-2017","volume":"111","author":"Roydhouse","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.jval.2024.09.009_bib15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jnci\/djac129","article-title":"Encouraging rigorous patient-generated data all along the drug development continuum","volume":"114","author":"Bhatnagar","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jval.2024.09.009_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the\u00a0Food and Drug Administration, and the patient","volume":"1","author":"Basch","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jval.2024.09.009_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s13142-011-0025-3","article-title":"Stakeholder perspectives on implementing the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Bruner","year":"2011","journal-title":"Transl Behav Med"},{"issue":"10","key":"10.1016\/j.jval.2024.09.009_bib19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.jval.2024.09.009_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju129","article-title":"Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials","volume":"106","author":"Reeve","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jval.2024.09.009_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1740774518799985","article-title":"Patient-Reported outcomes version of the common terminology criteria for adverse events: methods for item selection in industry-sponsored oncology clinical trials","volume":"15","author":"Trask","year":"2018","journal-title":"Clin Trials"},{"issue":"8","key":"10.1016\/j.jval.2024.09.009_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies\u00a0by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jval.2024.09.009_bib23","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","article-title":"Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group","volume":"24","author":"Piccinin","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2024.09.009_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/PROM.S256567","article-title":"Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE(\u00ae to provide two distinct and complementary perspectives","volume":"13","author":"Minasian","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"10.1016\/j.jval.2024.09.009_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41416-023-02307-w","article-title":"A\u00a0tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events","volume":"129","author":"Janse van Rensburg","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jval.2024.09.009_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jamia\/ocy169","article-title":"Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute\u2019s Patient-Reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"26","author":"Chung","year":"2019","journal-title":"J\u00a0Am Med Inform Assoc"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T02:38:08Z","timestamp":1767235088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524028626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1098301524028626"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.09.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}